

David W Boulton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2714938/publications.pdf>

Version: 2024-02-01

94
papers

3,706
citations

136950
32
h-index

138484
58
g-index

94
all docs

94
docs citations

94
times ranked

3829
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1353.	7.4	340
2	Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis. Diabetes, Obesity and Metabolism, 2018, 20, 479-487.	4.4	336
3	In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sciences, 2002, 71, 163-169.	4.3	235
4	Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes. Diabetes Care, 2013, 36, 3169-3176.	8.6	233
5	Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2. Clinical Pharmacokinetics, 2014, 53, 17-27.	3.5	180
6	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation, 2020, 142, 1040-1054.	1.6	128
7	The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. British Journal of Clinical Pharmacology, 2013, 76, 432-444.	2.4	98
8	Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin. Clinical Pharmacokinetics, 2011, 50, 253-265.	3.5	93
9	Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections. Drug Metabolism and Disposition, 2009, 37, 1164-1171.	3.3	89
10	Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study. Clinical Therapeutics, 2011, 33, 1798-1808.	2.5	75
11	Validation of 4Î²â€hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of <scp>CYP3A</scp> activity in healthy subjects. British Journal of Clinical Pharmacology, 2014, 78, 1122-1134.	2.4	73
12	Effects of the sodiumâ€glucose coâ€transporterâ€2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 2667-2673.	4.4	73
13	Simultaneous oral therapeutic and intravenous ¹⁴Câ€microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. British Journal of Clinical Pharmacology, 2013, 75, 763-768.	2.4	72
14	Differential Time Course of Cytochrome P450 2D6 Enzyme Inhibition by Fluoxetine, Sertraline, and Paroxetine in Healthy Volunteers. Journal of Clinical Psychopharmacology, 2002, 22, 169-173.	1.4	70
15	Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clinical Pharmacology and Therapeutics, 2001, 70, 48-57.	4.7	65
16	The Pharmacokinetics of Levosalbutamol. Clinical Pharmacokinetics, 2001, 40, 23-40.	3.5	64
17	Tolerability and Pharmacokinetics of Aripiprazole in Children and Adolescents With Psychiatric Disorders. Journal of Clinical Psychopharmacology, 2008, 28, 441-446.	1.4	56
18	Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin. Advances in Therapy, 2012, 29, 163-177.	2.9	50

#	ARTICLE	IF	CITATIONS
19	A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug-Drug Interactions with Orally Administered Medications. <i>Clinical Pharmacokinetics</i> , 2020, 59, 447-462.	3.5	50
20	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. <i>Cardiovascular Diabetology</i> , 2019, 18, 138.	6.8	48
21	Pharmacokinetics of Aripiprazole and Concomitant Carbamazepine. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 279-283.	1.4	47
22	Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1295-F1306.	2.7	46
23	In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes. <i>Human Psychopharmacology</i> , 2001, 16, 541-544.	1.5	44
24	Preclinical Pharmacokinetics and Metabolism of BMS-214778, a Novel Melatonin Receptor Agonist. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 760-772.	3.3	44
25	An Open-Label Study of Aripiprazole: Pharmacokinetics, Tolerability, and Effectiveness in Children and Adolescents with Conduct Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009, 19, 431-439.	1.3	42
26	Single-Dose Pharmacokinetics of Methylphenidate in CYP2D6 Extensive and Poor Metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 347-349.	1.4	42
27	Characterization of the In Vitro and In Vivo Metabolism and Disposition and Cytochrome P450 Inhibition/Induction Profile of Saxagliptin in Human. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1345-1356.	3.3	41
28	Biowaiver Approach for Biopharmaceutics Classification System Class 3 Compound Metformin Hydrochloride Using In Silico Modeling. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 1773-1782.	3.3	40
29	Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans. <i>Frontiers in Pharmacology</i> , 2014, 5, 274.	3.5	38
30	Effects of Hepatic or Renal Impairment on the Pharmacokinetics of Aripiprazole. <i>Clinical Pharmacokinetics</i> , 2008, 47, 533-542.	3.5	37
31	Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor. <i>Clinical Pharmacokinetics</i> , 2017, 56, 11-24.	3.5	37
32	The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 30-38.	4.7	36
33	Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 380-395.	2.5	33
34	Enantioselective disposition of albuterol in humans. <i>Clinical Reviews in Allergy and Immunology</i> , 1996, 14, 115-138.	6.5	32
35	Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2684-2693.	4.4	28
36	Pharmacokinetics and Tolerability of Intramuscular, Oral and Intravenous Aripiprazole in Healthy Subjects and in Patients with Schizophrenia. <i>Clinical Pharmacokinetics</i> , 2008, 47, 475-485.	3.5	27

#	ARTICLE	IF	CITATIONS
37	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 92-102.	2.4	27
38	Selective Reaction Monitoring of Negative Electrospray Ionization Acetate Adduct Ions for the Bioanalysis of Dapagliflozin in Clinical Studies. <i>Analytical Chemistry</i> , 2015, 87, 3247-3254.	6.5	26
39	Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2493-2498.	4.4	26
40	Hypotension and Bradycardia in a Healthy Volunteer following a Single 5 mg Dose of Olanzapine. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 104-106.	2.0	25
41	Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats. <i>International Journal of Neuropsychopharmacology</i> , 1999, 2, 17-23.	2.1	24
42	Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. <i>Diabetes Care</i> , 2019, 42, 318-326.	8.6	23
43	Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. <i>Clinical Pharmacology: Advances and Applications</i> , 2011, 3, 13.	1.2	22
44	A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 350-354.	2.4	20
45	Validation and application of a high-performance liquid chromatography/tandem mass spectrometry assay for sumatriptan in human plasma. <i>Biomedical Chromatography</i> , 2003, 17, 48-52.	1.7	20
46	Stability of an extemporaneously compounded levothyroxine sodium oral liquid. <i>American Journal of Health-System Pharmacy</i> , 1996, 53, 1157-1161.	1.0	19
47	Effect of a High-Fat Meal on the Pharmacokinetics of Saxagliptin in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 1211-1216.	2.0	19
48	Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Subjects. <i>Clinical Drug Investigation</i> , 2011, 31, 619-630.	2.2	19
49	Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 222-229.	2.5	19
50	A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. <i>Human Psychopharmacology</i> , 2009, 24, 145-152.	1.5	18
51	Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2782-2789.	3.2	18
52	Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 876-882.	4.4	18
53	Great Expectations in Stereochemistry: Focus on Antidepressants. <i>CNS Spectrums</i> , 2002, 7, 28-33.	1.2	17
54	Dietary levels of quinine in tonic water do not inhibit CYP2D6 in vivo. <i>Food and Chemical Toxicology</i> , 2003, 41, 1199-1201.	3.6	16

#	ARTICLE	IF	CITATIONS
55	Stability of Hydrocortisone Oral Suspensions Prepared from Tablets and Powder. <i>Annals of Pharmacotherapy</i> , 1995, 29, 987-990.	1.9	14
56	Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. <i>Clinical Therapeutics</i> , 2015, 37, 1517-1528.	2.5	14
57	A Pharmacometric Approach to Quantify the Impact of Chronic Kidney Disease and Hemodialysis on Systemic Drug Exposure: Application to Saxagliptin. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 126S-33S.	2.0	13
58	Bioequivalence of Saxagliptin/Metformin Immediate Release (IR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin IR Tablets in Healthy Adult Subjects. <i>Clinical Drug Investigation</i> , 2013, 33, 365-374.	2.2	13
59	Targeting Renal Glucose Reabsorption for the Treatment of Type 2 Diabetes Mellitus Using the SGLT2 Inhibitor Dapagliflozin. <i>Postgraduate Medicine</i> , 2012, 124, 62-73.	2.0	12
60	Bioequivalence of saxagliptin/dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00201.	2.4	11
61	Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. <i>Clinical Therapeutics</i> , 2016, 38, 99-109.	2.5	11
62	Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 798-806.	4.4	11
63	Evolving drug regulatory landscape in China: A clinical pharmacology perspective. <i>Clinical and Translational Science</i> , 2021, 14, 1222-1230.	3.1	11
64	Model-Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 108-118.	2.5	11
65	Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1820-1828.	2.4	10
66	Relationship of Dapagliflozin With Serum Sodium. <i>JACC: Heart Failure</i> , 2022, 10, 306-318.	4.1	10
67	Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 636-648.	2.0	9
68	Formulation and evaluation of a propanidid hydroxypropyl- β -cyclodextrin solution for intravenous anaesthesia. <i>International Journal of Pharmaceutics</i> , 1997, 159, 191-196.	5.2	8
69	Transplacental distribution of salbutamol enantiomers at Caesarian section. <i>British Journal of Clinical Pharmacology</i> , 1997, 44, 587-590.	2.4	8
70	One step purification of alpha1-acid glycoprotein from human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 784, 33-38.	2.3	8
71	Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 76-91.	2.5	8
72	Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1942-1946.	2.4	8

#	ARTICLE	IF	CITATIONS
73	Effects of sodium zirconium cyclosilicate on sodium and potassium excretion in healthy adults: a Phase 1 study. CKJ: Clinical Kidney Journal, 2021, 14, 1924-1931.	2.9	8
74	Î2-Agonist Eutomers. Treatments in Respiratory Medicine, 2002, 1, 305-311.	1.2	7
75	Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2. Regulatory Toxicology and Pharmacology, 2013, 67, 89-97.	2.7	7
76	Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study. Clinical Therapeutics, 2016, 38, 1890-1899.	2.5	6
77	Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, 2019, 21, 1381-1387.	4.4	6
78	Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, 2019, 21, 829-836.	4.4	6
79	Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease. Clinical Pharmacokinetics, 2021, 60, 517-525.	3.5	6
80	Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4-Mediated Metabolism of Saxagliptin. Journal of Clinical Pharmacology, 2022, 62, 1018-1029.	2.0	6
81	Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus. Journal of Clinical Pharmacology, 2022, 62, 1227-1235.	2.0	6
82	Validation and application of a sensitive assay for butorphanol in human plasma by high-performance liquid chromatography with tandem mass spectrometry detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 775, 57-62.	2.3	5
83	The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase. British Journal of Clinical Pharmacology, 2011, 72, 775-786.	2.4	5
84	Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects. Clinical Therapeutics, 2019, 41, 1545-1563.	2.5	5
85	A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 991-1000.	4.4	5
86	Bioequivalence and food effect of heat-stressed and non-heat-stressed dapagliflozin 2.5- and 10-mg tablets. International Journal of Pharmaceutics, 2016, 511, 288-295.	5.2	4
87	Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: <scp>A</scp> quantitative assessment using an integrative systems pharmacology model. Diabetes, Obesity and Metabolism, 2018, 20, 2034-2038.	4.4	4
88	Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the <scp>EXSCEL</scp> and <scp>SAVOR-TIMI</scp> 53 cardiovascular outcomes trials. Diabetes, Obesity and Metabolism, 2021, 23, 1101-1110.	4.4	4
89	Pharmacokinetic Interaction Study Between Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone in Healthy Subjects: An Open-Label Randomized Crossover Study. Clinical Pharmacology in Drug Development, 2019, 8, 549-558.	1.6	3
90	Interaction of Î2-adrenoceptor agonists with native cyclodextrins: Application to the development of chiral assays for terbutaline. Pharmaceutica Acta Helveticae, 1996, 71, 293-296.	1.2	2

#	ARTICLE	IF	CITATIONS
91	Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis. Journal of Clinical Pharmacology, 2022, 62, 541-554.	2.0	2
92	Evaluation of potential drug interactions with sodium zirconium cyclosilicate: a single-center, open-label, one sequence crossover study in healthy adults. CKJ: Clinical Kidney Journal, 2021, 14, 1808-1816.	2.9	1
93	SGLT2 Inhibition Is Predicted to Reduce LV End Diastolic Pressure: A Mathematical Modeling Analysis. FASEB Journal, 2019, 33, 531.17.	0.5	0
94	MO364: Population Pharmacodynamic Dose-Response Analysis of Serum Potassium Following Dosing With Sodium Zirconium Cyclosilicate. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0